揭示了一种新的β-环氧德克斯-苏克西布结合物在蛋白质组调节中的潜力
Noemi Bognanni1, Stefania Zimbone2, Maria Laura Giuffrida2
1Dipartimento di Scienze Chimiche, Università degli studi di Catania, V.le A.Doria, 6, 95125, Catania, Italy.
ChemMedChem
|October 16, 2025
概括
一种新型的苏克西布-β-环氧德克斯联体 (SB-CD) 有效地增强了蛋白质酶体活性. 这种合物减少了细胞中的蛋白质积累,显示了与蛋白质酶功能障碍相关的疾病的治疗潜力.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白质酶对蛋白质降解和维持细胞平衡至关重要.
- 蛋白质酶功能障碍与神经退行性疾病和癌症有关.
- 苏西布是一种已知的抗炎药物.
研究的目的:
- 设计和评估一种新型β-环氧德克斯连合物苏克西布 (SB-CD).
- 研究SB-CD对体外和细胞内蛋白质酶活性的影响.
- 评估SB-CD对蛋白酶体相关病理的治疗潜力.
主要方法:
- 合成和表征SB-CD的结合体.
- 使用净化的人类20S核心颗粒测试蛋白酶活性.
- 使用差异化人类神经母细胞瘤SH-SY5Y细胞 (dSHSY5Y) 的细胞研究.
- 高分辨率电子喷雾电离质谱仪用于细胞吸收和稳定性研究.
主要成果:
- SB-CD以剂量依赖的方式增强了20S蛋白质酶的蛋白质分解活性.
- SB-CD的疗效高于单独使用苏克西布松,其基米素类和素类活性EC50值较低.
- 通过SB-CD治疗,可以减少dSHSY5Y细胞中无化蛋白质的积累.
- 质谱测量证实了SB-CD内部化和细胞内的稳定性长达24小时.
结论:
- 新型SB-CD合物是一种有效的增强蛋白质酶活性.
- 在与蛋白质酶功能障碍相关的疾病中,SB-CD显示出治疗应用的前景.
- 需要进一步的研究来探索SB-CD的全部治疗潜力.
相关概念视频
The Proteasome Structure
1.6K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
1.6K
The Proteasome
10.1K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.1K
The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
Regulated Protein Degradation
8.7K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.7K
Drug Metabolism: Phase II Reactions
4.9K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.9K


